Eli Lilly Launches Discounted Mounjaro And Zepbound As Fight Against Compounded Imitations Escalates Amid Ongoing FDA Shortage Status Debate
Eli Lilly Launches Discounted Mounjaro And Zepbound As Fight Against Compounded Imitations Escalates Amid Ongoing FDA Shortage Status Debate
伊利·莉莉推出了打折的蒙加罗和泽普宝作为对原料物复制品爆发升级的反击，此举是在持续的FDA物品短缺状态辩论中进行的。
Eli Lilly (NYSE:LLY) is intensifying its efforts to combat imitation versions of its popular appetite-suppressing drugs, Mounjaro and Zepbound.
礼来（纽交所:LLY）正在加大力度打击其知名的抑食药物Mounjaro和Zepbound的仿制品。
What Happened: The pharmaceutical giant is seeking to end a regulatory designation that has permitted cheaper, off-brand versions to thrive. Lawyers for Eli Lilly have notified healthcare providers that shortages of Mounjaro and Zepbound are effectively over, despite the FDA not yet confirming this status, reported The Washington Post.
发生了什么：这家药品巨头正寻求结束一个允许廉价、非品牌版本繁荣的监管定义。据《华盛顿邮报》报道，礼来的律师已通知医疗服务提供者，Mounjaro和Zepbound的短缺问题已基本解决，尽管FDA尚未确认这种状态。
On Tuesday, Eli Lilly launched a discounted product, presenting it as a safer alternative to the off-brand medications. This move comes as the company faces competition from compounding...
礼来周二推出了一种折扣产品，将其作为非品牌药物的更安全替代...
登录免费看全文
登录/注册